Iketani Ryo

Researcher

基本情報

Profile and Settings

• 氏名

  Iketani Ryo

Affiliation

• Pharmacoepidemiology

Location

• Hatanodai Campus

Achievements

Published Papers

• 【医療系ビッグデータと薬剤疫学】　薬剤経済評価における医療系ビッグデータの応用可能性, 池谷　怜, 昭和医科大学雑誌, 85(5):354 - 363, Nov. 2025, Peer-reviewed, DOI:https://doi.org/10.14930/jsmu.85.5_354
• Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis., Iketani Ryo;Imai Shinobu, Biological & pharmaceutical bulletin, 46(4), 2023, Peer-reviewed, DOI:10.1248/bpb.b22-00710
• Impact of breakthrough trials on prescription trends of sodium‐glucose cotransporter‐2 inhibitors in Japan: An interrupted time‐series analysis, Ryo Iketani; Shinobu Imai, Journal of Clinical Pharmacy and Therapeutics, 47(11):1796 - 1804, Nov. 2022, Peer-reviewed
• Identification of individuals benefiting from the kakaritsuke-yakuzaishi (family pharmacist) system in Japan: a retrospective cohort study using an employment-based health insurance claims database, Ryo Iketani; Keiko Konomura, BMC Health Serv Res, 22(1):682 - 682, May 2022, Peer-reviewed
• Utility of the family pharmacist system: a retrospective cohort study using administrative claims data, Ryo Iketani; Keiko Konomura, 医療薬学, 47(9):453 - 463, Sep. 2021, Peer-reviewed
• Identification of Patients with Type 2 Diabetes Mellitus Requiring Concentrated Pharmaceutical Management in Health Insurance Pharmacies: Quantitative Evaluation Using Administrative Claims Data, Ryo Iketani; Keiko Konomura, 医療薬学, 47(1):10 - 24, Jan. 2021, Peer-reviewed
• Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis., Ryo Iketani; Daisuke Furushima; Shinobu Imai; Hiroshi Yamada, Parkinsonism & related disorders, 78:82 - 90, Jul. 2020, Peer-reviewed
• Risk stratification for physical morbidity using factors associated with atypical antipsychotic treatment in Parkinson's disease: A retrospective observational study using administrative claims data., Ryo Iketani; Shinobu Imai; Hiromasa Horiguchi; Daisuke Furushima; Kiyohide Fushimi; Hiroshi Yamada, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 76:189 - 194, Apr. 2020, Peer-reviewed
• Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial., Daisuke Furushima; Takuma Nishimura; Norikata Takuma; Ryo Iketani; Tomohito Mizuno; Yuji Matsui; Tohru Yamaguchi; Yu Nakashima; Shinji Yamamoto; Masanobu Hibi; Hiroshi Yamada, Nutrients, 12(1), Dec. 2019, Peer-reviewed
• Comparison of the association of risperidone and quetiapine with deteriorating performance in walking and dressing in subjects with Parkinson's disease: a retrospective cohort study using administrative claims data., Ryo Iketani; Shinobu Imai; Hiromasa Horiguchi; Daisuke Furushima; Kiyohide Fushimi; Hiroshi Yamada, International clinical psychopharmacology, 34(5):234 - 240, Sep. 2019, Peer-reviewed
• The Effect of Tea Catechins on Natural Killer Cell Activity in the Elderly: A Pilot Study, IKETANI Ryo; YAMADA Hiroshi; FURUSHIMA Daisuke; NISHIMURA Takuma; HIRAMA Yui; ONISHI Shintaro; KANBARA Hidetoshi; MORI Takuya; OTA Noriyasu; OHNO Yuko, Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 50(4):139 - 145, 2019, Peer-reviewed
• Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis., Iketani R; Ohno K; Kawasaki Y; Matsumoto K; Yamada H; Kishino S, Biological & pharmaceutical bulletin, 41(7):1017 - 1023, 2018, Peer-reviewed
• Regional differences in the safety of telaprevir-based triple therapy for chronic hepatitis C in Japan: a retrospective cohort study, R. Iketani; K. Ide; H. Yamada; Y. Kawasaki; N. Masaki, Japanese Journal of Drug Informatics, 2018, Peer-reviewed
• Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis, Ryo Iketani; Yohei Kawasaki; Hiroshi Yamada, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(11):1976 - 1982, Nov. 2017, Peer-reviewed
• Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study, Maiko Akutagawa; Kazuki Ide; Yohei Kawasaki; Mie Yamanaka; Ryo Iketani; Hiroshi Yamada; Naohiko Masaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(9):1525 - 1529, Sep. 2017, Peer-reviewed
• Behaviors in response to adverse events associated with health foods use. -Internet Survey on Consumers, Physicians and Pharmacists-, Chiba T; Sato Y; Kobayashi E; Ide K; Iketani R; Yamada H; Umegaki K, Food Hyg Saf Sci.(Shokuhin Eiseigaku Zasshi), 58:234 - 240, Jul. 2017, Peer-reviewed
• Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study, Kazuki Ide; Yohei Kawasaki; Ryo Iketani; Naohiko Masaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(5):645 - 649, May 2017, Peer-reviewed
• The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study, Ryo Iketani; Kazuki Ide; Hiroshi Yamada; Yohei Kawasaki; Naohiko Masaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(5):687 - 692, May 2017, Peer-reviewed